Categories
  • Semaglutide Impurities des-7-Thr-SMT
  • Semaglutide Impurities des-7-Thr-SMT

Semaglutide Impurities des-7-Thr-SMT

Semaglutide impurity (des-7-Thr-SMT) is a structural derivative that may be produced during the synthesis or degradation of the GLP-1 analog semaglutide. It is characterized by the absence of the threonine residue at position 7. As a drug impurity, its presence may affect the purity, efficacy or safety of semaglutide, so it needs to be strictly monitored and analyzed in drug development and quality control. The detection of this impurity is of great significance to ensure the stability and clinical effect of the diabetes treatment drug semaglutide.

  • Product Details

  • Technical Support

Product Overview

Basic Description

Structure and function:
1. des-7-Thr-SMT is an impurity of semaglutide that lacks the threonine residue at position 7.
2. This deficiency may affect its GLP-1 receptor binding ability and biological activity.
3. Due to the lack of a key amino acid residue, its overall structure and function may be affected.
In vitro and in vivo studies:
1. In in vitro experiments, the GLP-1 receptor activation ability of des-7-Thr-SMT was lower than that of semaglutide.
2. In vivo studies have shown that this impurity also reduces the effect of blood sugar control.
3. Studies in animal models have shown that this impurity may lead to decreased drug efficacy, but the specific mechanism needs further study.
4. Preclinical studies suggest that the safety of des-7-Thr-SMT needs further evaluation.

​Three-letter sequence​

His-Ala-Glu-Gly-Thr-Phe-Ser-Asp-Val-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly

​Single letter sequence​

HAEGETFSVDVYLGQAAKELIAWLVRGRG

Molecular formula

C178H259N45O54S

Molecular weight

4,051.9 g/mol

Product Attributes

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light


Instructions
  • Please store the product immediately according to the recommended conditions in the instructions upon receipt. Unless otherwise specified, all products are freeze-dried powders. Since trace amounts of peptides are deposited in the tube during the freeze-drying process, forming a very thin or invisible peptide layer, we recommend centrifuging at about 8,000-12,000g for 10-30 seconds in a centrifuge before opening the tube cap, so that the peptides attached to the tube cap or tube wall are aggregated at the bottom of the tube.
  • Please refer to relevant literature for the specific optimal working concentration, or explore and optimize through experiments based on the purpose of the experiment and specific cells and animals.
Our company can provide customized synthesis of high-polypeptide, virtual screening of compounds, Animal disease model construction,
Drug safety verification,
Application technology support for gene editing animals, etc.
For specific application consultation, please contact the sales department.

We look forward to your inquiries:

Sales Department 1: Manager Han
Mobile phone: 18701856899
WeChat: 18701856899
QQ: 1295139147
Email: 18701856899@163.com